4-(4-(5-(4-(difluoromethoxy)phenyl)pyrimidin-2-ylamino)benzoyl)-1-methylpiperazin-2-one | 1123514-43-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-(4-(5-(4-(difluoromethoxy)phenyl)pyrimidin-2-ylamino)benzoyl)-1-methylpiperazin-2-one
• 英文别名: 4-[4-[[5-[4-(Difluoromethoxy)phenyl]pyrimidin-2-yl]amino]benzoyl]-1-methylpiperazin-2-one
• CAS: 1123514-43-1
• 化学式: C₂₃H₂₁F₂N₅O₃
• 分子量: 453.448
• InChiKey: JESHSULZUYYILQ-UHFFFAOYSA-N

物化性质

• 沸点：
  700.8±70.0 °C(predicted)
• 密度：
  1.353±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  87.7
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  4-(5-(4-(difluoromethoxy)phenyl)pyrimidin-2-ylamino)benzoic acid 、 1-甲基哌嗪-2-酮 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 4-(4-(5-(4-(difluoromethoxy)phenyl)pyrimidin-2-ylamino)benzoyl)-1-methylpiperazin-2-one
  参考文献：
  名称：

  [EN] 5- (4- (HALOALKOXY) PHENYL) PYRIMIDINE-2-AMINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
  [FR] COMPOSÉS ET COMPOSITIONS DE 5- (4- (HALOALKOXY) PHÉNYL) PYRIMIDINE-2-AMINE UTILISÉS COMME INHIBITEURS DE KINASES

  摘要：

  该发明提供了式（1）的化合物及其制药组合物，可用作蛋白激酶抑制剂，以及使用这些化合物治疗、改善或预防与异常或调节的激酶活性相关的疾病的方法。在某些实施方式中，该发明提供了使用这些化合物来治疗、改善或预防涉及c-kit、PDGFRα、PDGFRβ、CSF1R、AbI、BCR-AbI、CSK、JNK1、JNK2、p38、p70S6K、TGFβ、SRC、EGFR、trkB、FGFR3、Fes、Lck、Syk、RAF、MKK4、MKK6、SAPK2β、BRK、Fms、KDR、c-rapor、b-raf激酶的疾病或紊乱的方法。

  公开号：

  WO2009026276A1

文献信息

• PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2185540A1

  公开（公告）日：2010-05-19
• 5- (4- (HALOALKOXY) PHENYL) PYRIMIDINE-2-AMINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
  申请人：IRM LLC

  公开号：EP2190825A1

  公开（公告）日：2010-06-02
• US8293757B2
  申请人：——

  公开号：US8293757B2

  公开（公告）日：2012-10-23
• [EN] PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS DE PYRROLIDINE ARYLE-ÉTHER UTILISÉS COMME ANTAGONISTES DES RÉCEPTEURS NK3
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009019163A1

  公开（公告）日：2009-02-12

  The invention relates to a compound of general formula (I) wherein Ar1 is aryl or a five or six membered heteroaryl; Ar2 is aryl or a five or six membered heteroaryl; R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, S-lower alkyl, -S(O)2-lower alkyl, -S(O)2-di-lower alkyl amino, -(CH2)qR, cyano, amino, mono or di-lower alkyl amino, NHC(O)-lower alkyl, cycloalkyl or is or a five membered heteroaryl, optionally substituted by lower alkyl; wherein R is cyano, di-lower alkyl amino or pyrrolidin-1-yl; R2 is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen or cyano; R3 is hydrogen or lower alkyl or CH2OH; R4 is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen or cyano; n is 1, 2 or 3; in case n is 2 or 3, R1 may be the same or different; o is 1, 2 or 3; in case o is 2 or 3, R2 may be the same or different; p is 1, 2 or 3; in case p is 2 or 3, R4 may be the same or different; q is 1 or 2; or to a pharmaceutically active salt thereof, including all stereoisomeric forms, individual diastereoisomers and enantiomers of the compound of formula (I) as well as racemic and non-racemic mixtures thereof. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).